SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-081980
Filing Date
2024-09-26
Accepted
2024-09-26 08:32:02
Documents
3
Period of Report
2024-09-26

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0215700-6k_enlivex.htm 6-K 14515
2 PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON SEPTEMBER 26, 2024 ea021570001ex99-1_enlivex.htm EX-99.1 15340
3 GRAPHIC ex99-1_001.jpg GRAPHIC 7432
  Complete submission text file 0001213900-24-081980.txt   41525
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 241326240
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)